Bayer’s Kerendia Officially Launched in China for Type 2 Diabetes-Related CKD
German pharmaceutical giant Bayer’s (ETR: BAYN) Kerendia (finerenone), the first nonsteroidal, selective mineralocorticoid receptor (MR)...
Company
Sensview Secures Tens of Millions in Series A+ Funding for X-Ray Detector Tech
Sensview, a developer of solid-state imaging chips and detector module products based in Chengdu, has...
Nanjing Enrui Kainuo Biotechnology Secures Pre-Series A Funding for Cell Therapy Development
Nanjing Enrui Kainuo Biotechnology Co., Ltd, a China-based cell therapy developer, has reportedly raised tens...
Shenzhen Salubris Pharmaceuticals Receives FDA Clearance for SAL0119 Clinical Trial
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, has announced that it...
Bio-Thera Solutions Receives NMPA Approval for CTLA-4 and PD-1 Inhibitor Combo Study
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that it has received approval from China’s...
Shanghai Pharmaceuticals Gets NMPA Green Light for Recombinant Human Adenovirus Type 5 Trial
Shanghai Pharmaceuticals (HKG: 2607; SHA: 601607), a leading pharmaceutical company in China, has announced that...
Nanjing Immunophage Biotech’s IPG11406 Approved for SLE Clinical Trial in China
Nanjing Immunophage Biotech Co., Ltd, a China-based biotechnology company, has announced that it has received...
Pyrotech (Beijing) Biotechnology Secures $97.37 Million in Series A Financing
China-based biotech firm Pyrotech (Beijing) Biotechnology Co., Ltd announced the successful completion of a CNY...
Shanghai Henlius Biotech Announces Executive Leadership Changes
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced significant changes in its executive leadership....
Zai Lab and argenx Report Positive Preliminary Results from Vyvgart Hytrulo CIDP Study
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its Netherlands-based partner argenx SE (NASDAQ:...
ObsEva SA Regains Full Rights to Nolasiban After Terminating Yuyuan Biological License Deal
Swiss biopharmaceutical company ObsEva SA (SIX: OBSN) has announced that it has regained full rights...
Janssen’s Rybrevant Meets Primary Endpoint in Phase III NSCLC Study
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from...
Antengene Corp., Ltd Receives Hong Kong NDA Approval for Xpovio in Relapsed Multiple Myeloma
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced receiving New Drug Application (NDA)...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-A1811 and Pyrotinib Combo Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Shanghai Xinhengrui Medical Technology Secures Series A Funding for Heart Failure Device Development
Shanghai Xinhengrui Medical Technology Co., Ltd, a manufacturer of heart failure devices, has successfully raised...
Beyond Therapeutics Secures Tens of Millions in Pre-Series A Financing for Ophthalmology and Oncology Pipeline
Beyond Therapeutics Co., Ltd., a biotechnology company based in Suzhou with a focus on ophthalmology...
Mabwell Bioscience Receives NMPA Approval to Launch 9MW2921 Clinical Study
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...
Centre Medical Secures Tens of Millions in Series A Financing to Expand Globally
Centre Medical, a Hong Kong-based cardiovascular specialized medical services provider, has reportedly raised tens of...
TransThera Sciences’ TT-00420 Receives Breakthrough Designation for Cholangiocarcinoma Treatment
The Center for Drug Evaluation (CDE) website has indicated that Nanjing-based TransThera Sciences (Nanjing), Inc.’s...
Shenzhen Salubris Pharmaceuticals’ SAL0120 for IgA Nephropathy Accepted for NMPA Review
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that the National Medical Products Administration...